Amcor halts share trading; is Alcan Pharma Packaging deal close?
Amcor has temporarily halted trading on the Australian stock exchange, fuelling rumours that the group is finally about to move for Rio Tinto’s Alcan pharmaceutical packaging unit.
Sanofi to buy Indian vaccine biz
Sanofi-Aventis is continuing to expand in emerging markets by agreeing to acquire Indian vaccine manufacturer Shantha Biotechnics in a deal that values the company at €550m ($784m).
P&G close to finding buyer for its pharma unit
Procter & Gamble (P&G) is close to finding a buyer for its pharmaceutical division for around $3bn according to various media reports.
Alcan talks still on in wake of Bemis deal, says Amcor
Australian group Amcor has confirmed that talks about a takeover of Alcan’s pharmaceutical packaging business are still ongoing but says that no binding agreement has yet been reached.
Pfizer may bid for Turkey’s Abdi Ibrahim
Rumours suggest that US drug giant Pfizer is considering a bid for Turkish generics group Abdi Ibrahim as part of its strategy of expanding in emerging markets.
BASF expanding China JV
BASF and Sinopec are to invest $1.4bn (€1bn) in expanding their Chinese specialty chemical joint venture, adding 10 plants and increasing capacity at three existing sites.
NJ pharma employment down in ‘08
The number of pharma employees in New Jersey, US fell by 1,400 in 2008, with R&D expenditure, capital investment and product trials also declining, according to a report.
Mega deals not ‘mega’ for Big Pharma R&D long term, says F&S
As rumours of a failed Sanofi Aventis’ bid for a US rival circulate, F&S’ analysis of M&As is well timed, even if its conclusions will be difficult reading for a Big Pharma sector set on replenishing pipelines via big deals.
Sanofi swoops for Pfizer insulin plant, scuppering MannKind's bid
Sanofi Aventis will pay Pfizer €30m ($41m) for a former Exubera manufacturing plant in Frankfurt-Höchst, Germany that was due to be bought by inhaled insulin specialist MannKind.
Merge Healthcare to acquire eTrials after Bio-Imaging bid collapses
IT solutions firm Merge Healthcare has won the race to buy eClinical specialist etrials, beating previous suitor Bio-Imaging Technologies whose takeover bid collapsed on Monday.
UK trade office may check GSK and Pfizer HIV joint-venture
GSK and Pfizer’s HIV joint venture (JV) may be subject to an investigation by UK competition watchdog the Office of Fair Trading (OFT), according to various media reports.
in-Pharmatechnologist's Nick Taylor looks back on BIO 2009, an event at which uncertainty about the development of the biotechnology industry’s future shape dominated proceedings.
Pfizer eyes FOBs and small to midsized deals
Pfizer is monitoring opportunities in follow-on biologics and continuing to look for small to mid-sized deals as it plans for life without Lipitor, global revenues of which fell by 13 per cent in Q1.
Domino increases Portuguese footprint with €7m buy
Domino Printing is expanding its presence in Portugal through the €7m ($9m) acquisition of Labeljet SA and its subsidiary Marque TDI, which is currently a distributor for the traceability specialist.
China still important for Big Pharma despite M&A slowdown
Although the downturn has slowed Big Pharma’s investment in China, the country’s wide ranging healthcare reforms and changing economic landscape still provide considerable opportunities says PricewaterhouseCoopers (PwC).
Sanofi beats Teva in Medley melee
Sanofi Aventis has confirmed it is buying Brazil’s Medley for $664m (€500m), to position it as the largest player in South America’s generics market.
Cash strapped MDRNA sells CMO unit to Par
MDRNA is selling its manufacturing business to US generics firm Par Pharmaceuticals in a bid to boost its coffers and complete its transformation into a purely RNAi focused organisation.
Sanofi leads pack in €5bn+ pursuit of Solvay; reports
Sanofi-Aventis had a €5bn ($6.6bn) bid for Solvay’s pharma business rejected, according to media reports, but several other companies are believed to be interested in the Belgian firm.
Winpak wins Reynolds’ Packaging license race
Canada’s Winpak has gained an exclusive license to use Reynolds Packaging’s manufacturing know-how in the production of packaging for the drug and healthcare industries.
Novartis bids for greater share of Indian subsidiary
Novartis is looking to buy an additional 39 per cent of its majority-owned subsidiary Novartis India for around 4.4bn rupees ($87m), or 351 rupees per share.
GSK may move for Botox maker Allergan
The pharmaceutical rumour mill is still spinning with the latest speculation that UK drug major GSK is interested in Botox manufacturer Allergan causing the US firm’s share price to leap 13 per cent on the New York Stock Exchange.
The global economic downturn, impending blockbuster patent expiries and the wave of consolidation sweeping the pharmaceutical industry will drive demand for Patheon’s restructuring service according to CEO Wesley Wheeler.
Skin care firm Stiefel considers $4bn sale
Dermatology drug specialist Stiefel Laboratories may be looking for a Big Pharma buyer according to various media reports.
Merck moves for Schering in $41bn mega-merger
The year of the mega-merger continues with Merck & Co’s move to buy Schering-Plough for $41.1bn, with the intention of boosting its pipeline, entering new markets and creating a “powerful biologics presence”.
Merck & Co to pay $41bn for Schering Plough
Merck & Co is to buy fellow US drug major Schering Plough for $41bn (€32.6bn) to boost its pipeline in the face of impending patent expiry for key products.
Genentech to Roche: We’re equipped for hard times
Genentech believes a far-sighted approach to patent expiration, unique and life saving drugs and an unrivalled scientific culture will protect it from recession and ensure greater growth than Roche envisions.
Piramal won’t “dilute ownership,” or comment on Sanofi rumours
Indian generics firm Piramal Healthcare says it "has no intention to dilute current ownership levels," but has not commented on rumours that it is in talks with French firm Sanofi Aventis.
"Anywhere, anytime" – Genentech challenges Roche
Genentech used its investor meeting to retaliate against criticisms made by Roche, saying it will debate its financial model “anywhere, anytime with anyone”.
Multinational deals set to continue in Indian pharma
The Indian pharmaceutical and biotech sectors may see more M&A activity this year with rumours that GSK, Sanofi Aventis and Merck KGaA are on the look out for potential deals.
Sanofi "no comment" on deal for Brazil's Medley
French drug major Sanofi Aventis is in talks about taking over market leading Brazilian generics firm Medley, according to reports the country’s Valor Economico newspaper.
Sanofi won’t follow mega-merger plan like Pfizer’s, says CEO
New Sanofi Aventis chief Christopher Viebacher has virtually ruled out major acquisitions, eschewing the trend started by Pfizer’s $68bn (€53bn) swoop for Wyeth in favour of an anti-mega merger stance like that adopted by UK rival GSK.
Genentech wanted $112 per share from Roche; SEC filing
The strained relationship between Genentech and Roche has been revealed in a SEC filing, which details their differing valuations and accusations of misleading financial models.
Amcor in talks for Alcan’s packaging unit
Australian packaging company Amcor is in talks with mining giant Rio Tinto about buying part of the latter’s Alcan Packaging Division, confirming speculation that emerged late last year.
Genentech “disappointed” at Roche’s hostile action
Roche has stepped up its pursuit of Genentech, launching a hostile bid of $42bn after growing frustrated with the lack of progress over the past six months.
M&A fever sweeps drug industry in wake of Pfizer-Wyeth deal
Pfizer’s $68bn swoop for Wyeth looks set to start an epidemic of merger madness according to comments by Frost & Sullivan (F&S) analyst Shabeer Hussain.
Pfizer to acquire Wyeth in $68bn deal
Pfizer has confirmed it has entered into an agreement to buy Wyeth in a deal worth $68bn, which it hopes will strengthen its position in anticipation of a challenging few years.
Sanofi to sell liquid drugs plant to Unither
Sanofi-Aventis is to sell its liquid drug manufacturing plant in Colomiers, southwest France, to industry specialist Unither for an as yet undisclosed sum.
Hectic week of M&A led by the return of King to Alpharma
King Pharmaceuticals’ $1.6bn (€1.2bn) acquisition of Alpharma heads a busy week of deals that has seen J&J agree to pay $438m for Omrix and India’s Sun further its presence in the US narcotic APIs sector through the purchase of Chattem Chemicals.
Reshaping R&D replaces cost cutting as top priority
Cost cutting has sustained pharma profits in the faltering global economy, however top executives are starting to realise that reducing R&D capacity may not have been the smartest move in an era of weak pipelines and impending patent expiry, according...
RCP’s big plans for nanotechnology
Robert Sexauer, CEO of biopharmaceuticals group RCP Therapeutics, says the R&D investment deal signed with FirstPoint Biotech shows the attractiveness of the firm’s nano-medical pipeline, particularly given the current economic climate.
Lilly to acquire ImClone for $6.5bn
Eli Lilly has agreed to acquire ImClone for $6.5bn and in doing so appears to have snatched the biotech away from Bristol-Myers Squibb (BMS), which first tabled a bid back in July.
Teva Kowa JV to target Japanese generics market
Teva and Kowa have set their sights on Japan’s $4.6bn (€3.1bn) generics market with their development and manufacturing joint venture Teva-Kowa Pharma.
Zentiva board accepts Sanofi’s revised €1.8bn offer
Sanofi-Aventis’ €1.8bn ($2.6bn) offer for Czech generics firm Zentiva has been unanimously accepted by the latter firm’s board after four months of wrangling that has seen the bid increase by 9.5 per cent.
Israeli court rules against “disingenuous” Taro
The Tel-Aviv District Court has found in favour of Sun Pharmaceuticals in its long running struggle to acquire Israeli drug and pharmaceutical ingredient maker Taro Pharmaceutical Industries.
Genentech rejects Roche but leaves door ajar
Genentech’s special advisory committee has rejected Roche’s $44bn offer for the biotech believing that it “substantially undervalues” the company.
APC parent to be bought by Otsuka Chemical
US protein manufacture and development services provider American Peptide Company (APC) says that its parent company, Ito Life Sciences (ILS), is to be acquired by fellow Japanese firm Otsuka Chemical.
MeadWestvaco and Bilcare jointly buy packaging firm
Contract packaging company International Labs has been taken over in a joint acquisition between India’s Bilcare and MeadWestvaco of the US.
Teva pounces on Barr with $7.5bn offer
There looks set to be further consolidation in the generics sector with Teva offering to acquire Barr Pharmaceuticals in a deal worth $7.5bn
Brookwood acquisition expands delivery portfolio
Brookwood Pharmaceuticals, a subsidiary of SurModics, has acquired the exclusive rights to all pharmaceutical applications of PharmaSol’s nanostructured lipid carrier (NLC) technology.
Sinclair and Wockhardt strike deal
UK-based Sinclair Pharmaceuticals has entered into a manufacturing
and distribution agreement with Wockhardt, an Indian pharmaceutical
and biotech company.